SUN PHARMA - All Targets Dusted!

SUN PHARMA - All Targets Dusted!

Market Overview
Sun Pharmaceutical, India's largest drugmaker, is positioning itself in the lucrative anti-obesity and type 2 diabetes drug market. The company aims to launch its experimental drug within four to five years, capitalizing on the projected $150 billion global market by 2030. This long-term growth potential aligns with the recent bullish momentum in Sun Pharma’s stock price.

Technical Analysis (15-Min Chart)
All targets have been successfully hit, confirming a strong long trade setup.


Entry Level: ₹1593.05
Stop-Loss (SL): ₹1587.55 (remained protected)
Take Profit Levels (TPs):
TP1 (₹1599.85) ✅ Achieved
TP2 (₹1610.85) ✅ Achieved
TP3 (₹1621.85) ✅ Achieved
TP4 (₹1628.65) ✅ Final target reached


Key Technical Indicators:
RIsological Indicator: Bullish confirmation on the Risological indicator.
Strong Trendline Support: The stock maintained higher lows, sustaining an uptrend.
Volume Surge: Increased buying pressure fueled the move toward TP4.

Trade Performance & Future Outlook
Successful Execution: The trade played out perfectly, hitting all projected targets.
Profit Booking Recommended: As all TPs are done, traders should consider locking in gains.
Watch for Re-Entry: A pullback to ₹1610–₹1599 levels may offer a fresh buying opportunity.

Sun Pharma's strong uptrend, backed by fundamental growth drivers, made this trade a high-conviction long setup. With the obesity drug pipeline in focus, the stock may continue to attract investor interest. Traders should wait for retracements before initiating new positions.

Read More

Share:

Latest News